stockrow
Saturday 7 November 2026
Export AKTS’s income statement to Excel — free account
Aktis Oncology, Inc.
AKTS Healthcare Biotechnology
Aktis Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.5 million, up 336.9% from fiscal 2024.
15.78
0.93
+6.26%
Follow AKTS
Alert me
| Older periods | Jun '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+3 more quarters Free account |
0.00 | — | 0.00 | 0.00 |
P/S ratio |
0.00 | — | 0.00 | 184.52 | |
P/FCF ratio |
0.00 | — | 0.00 | 0.00 | |
P/Operating CF |
(0.28) | — | (35.89) | (86.58) | |
P/B ratio |
0.00 | — | 1.72 | 3.68 | |
Price to Tangible BV |
0.00 | — | 1.72 | 3.68 | |
EV/Sales |
0.00 | — | 0.00 | 130.97 | |
EV/EBITDA |
0.00 | — | 0.00 | 0.00 | |
EV/Operating CF |
2.51 | — | (2.72) | (10.11) | |
EV/FCF |
2.11 | — | (2.42) | (9.08) | |
Quick Ratio |
— | 7.26 | 19.29 | 16.10 | |
Current Ratio |
— | 7.37 | 19.49 | 16.33 | |
Net Debt/EBITDA |
0.00 | 0.00 | 23.84 | 17.81 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
— | 0.00 | 0.00 | 0.03 | |
Operating CF/Net income |
0.90 | 0.00 | 1.32 | 0.85 | |
Capex/Depreciation |
2.01 | 4.18 | (15.07) | 8.19 | |
Research and Development Expense of Revenue |
1,163.52% | — | 620.89% | 747.04% | |
Selling, General and Administrative Expense of Revenue |
245.85% | — | 182.74% | 206.94% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
94.82% | — | 93.65% | 95.21% | |
Graham Net Nets |
8.44 | — | 0.54 | 0.25 | |
Graham Number |
0.00 | — | 0.00 | 0.00 | |
Earnings Yield |
(129.71%) | — | (129.71%) | (129.71%) | |
Free Cash Flow Yield |
(546.91%) | — | (15.74%) | (7.82%) | |
Revenue per Share |
1.98 | — | 0.07 | 0.06 | |
Operating CF per Share |
(20.04) | 0.00 | (0.50) | (0.37) | |
Capex per Share |
(1.90) | 0.00 | (0.04) | (0.02) | |
Free Cash Flow per Share |
(21.94) | 0.00 | (0.54) | (0.40) | |
Cash per Share |
0.00 | 0.00 | 11.07 | 9.35 | |
Shareholders Equity per Share |
0.00 | 0.00 | 10.41 | 8.77 | |
Interest Debt per Share |
0.00 | — | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | 10.41 | 8.77 | |
Free Cash Flow |
(17.71) | (73.71) | (26.10) | (21.85) | |
Working Capital |
— | 199.07 | 516.03 | 492.41 | |
Capital Expenditures |
(1.53) | (9.58) | (1.85) | (1.26) | |
Net Current Asset Value |
0.00 | 152.69 | 473.25 | 451.78 | |
EV/EBIT |
0.00 | — | 0.00 | 0.00 | |
Capex to Sales |
0.96 | 0.00 | 0.57 | 0.37 | |
Price to Operating Income |
0.00 | — | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
— | — | — | 1.75 | |
Average Assets |
— | 193.62 | 451.49 | 339.98 | |
Average Common Equity |
— | — | — | 219.27 |
Columns are period end dates · fundamentals updated 26 Oct 2026